# Novartis AG: overview NVS · NYSE · CIK 1114448 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nvs.md) · [Financials](/companies/nvs/financials.md) · [Filings](/companies/nvs/filings.md) · [Insiders](/companies/nvs/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $bn | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [10.63](/filings/0001370368-24-000004.md) | [3.17](/filings/0001370368-25-000004.md) | [7.10](/filings/0001114448-26-000004.md) | [5.87](/filings/0001114448-26-000004.md) | [7.15](/filings/0001114448-26-000004.md) | | Free cash flow | $bn | [14.0](/filings/0001370368-24-000004.md) | [13.3](/filings/0001370368-25-000004.md) | [13.4](/filings/0001114448-26-000004.md) | [16.3](/filings/0001114448-26-000004.md) | [17.6](/filings/0001114448-26-000004.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nvs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Fisher Asset Management, LLC](/funds/850529.md) | 2026-06-30 | $2.43bn | 15,523,378 | | Added +1,637,629 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.37bn | 8,726,827 | | Added +199,790 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $1.27bn | 8,117,586 | | Added +7,470 | | [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $1.03bn | 6,592,124 | | Reduced −975,230 | | [LOOMIS SAYLES & CO L P](/funds/312348.md) | 2026-06-30 | $821.1m | 5,239,309 | | Reduced −186,791 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $769.5m | 4,909,938 | | Reduced −52,856 | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $509.5m | 3,251,281 | | Reduced −158,663 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $477.7m | 3,047,988 | | Added +98,228 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $467.1m | 2,980,168 | | Reduced −3,545,603 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $437.7m | 2,792,745 | | Added +6,517 | ## Recent filings [All 1,027 filings](/companies/nvs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 06:08 ET | [6-K](/filings/0001114448-26-000014.md) | Report of a foreign private issuer, period 2026-09-30 | 0001114448-26-000014 | | 2026-09-08 | 06:05 ET | [6-K](/filings/0001171843-26-005908.md) | Report of a foreign private issuer, period 2026-09-08 | 0001171843-26-005908 | | 2026-09-04 | 17:22 ET | [6-K](/filings/0001171843-26-005896.md) | Report of a foreign private issuer, period 2026-09-04 | 0001171843-26-005896 | | 2026-09-01 | 06:21 ET | [6-K](/filings/0001171843-26-005824.md) | Report of a foreign private issuer, period 2026-09-01 | 0001171843-26-005824 | | 2026-07-21 | 06:25 ET | [6-K](/filings/0001114448-26-000012.md) | Report of a foreign private issuer, period 2026-06-30 | 0001114448-26-000012 | | 2026-06-11 | 07:58 ET | [6-K](/filings/0001171843-26-004052.md) | Report of a foreign private issuer, period 2026-06-11 | 0001171843-26-004052 | | 2026-04-28 | 06:21 ET | [6-K](/filings/0001114448-26-000010.md) | Report of a foreign private issuer, period 2026-03-31 | 0001114448-26-000010 | | 2026-03-18 | 16:23 ET | [6-K](/filings/0001104659-26-031037.md) | Report of a foreign private issuer, period 2026-03-18 | 0001104659-26-031037 | | 2026-02-04 | 06:52 ET | [6-K](/filings/0001114448-26-000008.md) | Report of a foreign private issuer, period 2025-12-31 | 0001114448-26-000008 | | 2026-02-04 | 06:51 ET | [6-K](/filings/0001114448-26-000007.md) | Report of a foreign private issuer, period 2025-12-31 | 0001114448-26-000007 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001114448-26-000004.md), filed Feb 4, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1114448 - Tickers: NVS, NVSEF - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: V8 - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:27 ET. No prices; not investment advice.